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Received September 11, 2015; accepted February 15, 2016AbstractBackground: To assess the pregnancy outcome and ovarian hyperstimulation syndrome (OHSS) incidence in high responders receiving
gonadotropin-releasing hormone agonist (GnRHa) trigger plus individualized support of low-dose human chorionic gonadotropin (hCG). Such
support includes 500e1000 IU hCG given at trigger and, if serum estradiol (E2) dropped to below 800 pg/mL before the 6
th day after oocyte
retrieval, an additional rescue dose of 300 IU hCG.
Methods: This was a retrospective study of potential high responders aged from 28 years to 40 years at a tertiary fertility center in Taiwan. By
means of chart review, we assessed the pregnancy outcome and OHSS incidence in high responders receiving GnRHa trigger plus individualized
low-dose hCG support. The main outcomes were measured by ongoing pregnancy rate and OHSS incidence (SPSS), in which statistical sig-
nificance was determined by Chi-square test.
Results: Moderate to severe OHSS did not develop in any patient receiving GnRHa trigger plus individualized low-dose hCG support. In fact, a
satisfactory ongoing pregnancy rate (46.9%) was noted in patients receiving GnRHa trigger plus individualized low-dose hCG support.
Conclusion: Our study suggested that GnRHa trigger combined with individualized low-dose hCG support appears to be a safe approach with a
satisfactory pregnancy outcome.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Ovarian hyperstimulation syndrome (OHSS) remains the
most challenging complication in assisted reproductive tech-
nology, which potentially puts the patient into life-threatening
danger.1 Conventional use of human chorionic gonadotropin
(hCG) for triggering, due to its sustained and considerablyConflicts of interest: The authors declare that they have no conflicts of interest
related to the subject matter or materials discussed in this article.
* Corresponding author. Dr. Hsin-Yang Li, Division of Reproductive
Endocrinology and Infertility, Department of Obstetrics and Gynecology,
Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112,
Taiwan, ROC.
E-mail address: lihy@vghtpe.gov.tw (H.-Y. Li).
http://dx.doi.org/10.1016/j.jcma.2016.02.006
1726-4901/Copyright © 2016, the Chinese Medical Association. Published by El
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).more powerful luteotropic activity, increases the risk of
OHSS.1,2 Previous studies have proposed replacing hCG with
gonadotropin-releasing hormone agonist (GnRHa) to induce a
surge of luteinizing hormone (LH),3,4 by which OHSS risk can
be eliminated.5 Although the GnRHa-induced LH surge
effectively stimulates final oocyte maturation,4,6 due to the
short duration of LH secretion and the status of pituitary
desensitization, luteolysis occurs more rapidly compared to the
natural cycles.5,7 More and more evidence including that from
the Cochrane Review has corroborated that GnRHa trigger in
antagonist protocols did prevent OHSS5,6,8 but led to unfa-
vorable rates of ongoing pregnancy and live birth,6,8,9 which
mainly stemmed from defective corpus luteal function.10,11
Therefore, adequate luteal phase support is essential to main-
tain a successful pregnancy in GnRHa-triggered cycles.sevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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modified luteal phase support to enhance reproductive out-
comes. Engmann et al12 reported an ongoing pregnancy rate of
53.3% in GnRHa-triggered cycles that are supported by
intramuscular (IM), progesterone (P), and transdermal estra-
diol (E2) in the luteal phase. As described by Shapiro et al,
13
“dual trigger”, in which a reduced dose (1000e2500 IU) of
hCG was administered along with the triggering agonist, was
also associated with excellent reproductive outcome. By
contrast, Humaidan et al14 suggested that 1500 IU of hCG
could be given 35 hours after GnRHa trigger to rescue the
corpus luteum. To the best of our knowledge, there seems to be
a lack of consensus regarding the most effective and safest
protocol for high responders.
Inspired by the aforementioned literature, we developed an
individualized low-dose hCG support, in which the patients
were dually triggered with GnRHa and an even lower dose
(500e1000 IU) of hCG followed by luteal phase support with
IM, P, and oral E2 in combination with or without an extra
rescue dose (300 IU) of hCG (depending on E2 level in the
luteal phase). The purpose of this present study was to
compare the reproductive outcomes and OHSS incidence in
high responders that were divided into four groups: (1) trig-
gered with hCG under downregulation protocol, (2) triggered
with hCG under GnRH antagonist protocol, (3) triggered with
GnRHa alone under GnRH antagonist protocol, and (4)
receiving GnRHa-triggered GnRH antagonist protocol with
“individualized low-dose hCG support”, i.e., dually triggered
by GnRHa and 500e1000 IU of hCG with or without a rescue
dose (300 IU) of hCG in the luteal phase.
2. Methods2.1. PatientsFig. 1. Treatment protocols. Group A, downregulation protocol with hCG
trigger; Group B, GnRH antagonist protocol with hCG trigger; Group C, GnRH
antagonist protocol with GnRHa trigger; and Group D, GnRH antagonist pro-
tocol with GnRHa trigger combined with individualized low-dose hCG support
(Please refer to Fig. 2A for the detail of individualization in Group D.).
E2V ¼ estradiol valerate; ET ¼ embryo transfer; IM P ¼ intramuscular pro-
gesterone; IVF/ICSI ¼ in vitro fertilization and/or intracytoplasmic sperm in-
jection; OR ¼ oocyte retrieval; rFSH ¼ recombinant follicle-stimulating
hormone; Vag P ¼ vaginal-route micronized progesterone (Crinone).A retrospective study was conducted at the Center for
Reproductive Medicine in Taipei Veterans General Hospital,
Taipei, Taiwan, and undertaken by means of chart review.
From January 2009 to September 2011, we applied GnRHa
trigger combined with individualized low-dose hCG support in
34 cycles, and GnRHa trigger alone in 23 cycles, to potential
high responders with polycystic ovarian morphology (PCOM),
polycystic ovarian syndrome (PCOS), or previous OHSS. In
the aforementioned cycles, the serum level of E2 on the day of
trigger, i.e., peak E2, ranged between 2500 pg/mL and
13478 pg/mL. To recruit matching cases triggered by hCG
with comparable peak E2, cycles with peak E2  2500 pg/mL
were enrolled. We excluded patients with one of the following
conditions: (1) older than 40 years, (2) endometriosis, (3)
hypogonadotropic hypogonadism, (4) freezing cycles, and (5)
uterine abnormalities. In the study period, a total of 155 cycles
were included in this retrospective study. As the study was
merely performed via chart review, which included only
analysis of data from routine clinical practice, it did not
require submission to our Institutional Review Board.
Informed consent was obtained from each patient who was
included in the study.2.2. Treatment protocolsOvarian stimulation was performed with recombinant
follicle-stimulating hormone (rFSH), with the starting dose
determined by the patient's age, body mass index (BMI), basal
FSH level, and antral follicle count. During stimulation, the
dose of rFSH was adjusted by ovarian response monitored
every other day from the 4th day of stimulation. A simplified
schematic description of the four treatment protocols is shown
in Fig. 1. Patients receiving protocol A were downregulated
with daily leuprolide 0.5 mg subcutaneously (sc) from the
preceding midluteal phase, and the dose of leuprolide was
lowered to 0.25 mg from the starting day of rFSH stimulation.
In Groups BeD, daily cotreatment with antagonist cetrorelix
0.25 mg sc was initiated either once the leading follicle had
reached a size of 14 mm or no later than the 6th day of rFSH
stimulation. The patients were triggered when at least three
leading follicles reached above 17 mm in diameter. Oocytes
were retrieved 34e36 hours after trigger, followed by in vitro
fertilization (IVF) and/or intracytoplasmic sperm injection
(ICSI) according to the condition of the sperm.
In Groups A and B, 10,000 IU of hCG was injected to
trigger final oocyte maturation, followed by luteal phase sup-
port consisting of micronized progesterone vaginally (90 mg/d;
Crinone; Merck Serono, Geneva, Switzerland) and oral estra-
diol valerate (6 mg/d). In Group C, triptorelin (Decapeptyl;
Ferring Pharmaceuticals, Saint-Prex, Switzerland) 0.2 mg was
sc administered for triggering, and IM progesterone injection
(100 mg/d) along with oral estradiol valerate (6 mg/d) was
prescribed for luteal support. Patients in Group D were dually
triggered by triptorelin 0.2 mg and hCG with a dose depending
on the serum level of E2 and the number of follicles  11 mm
on trigger day (500 IU for cycles with peak E2 > 5000 pg/mL
or follicle number  25,750 IU for cycles with peak E2
3500e5000 pg/mL and follicle number < 25, and 1000 IU for
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Luteal support for cycles in Group D included IM progesterone
(100 mg/d), oral estradiol valerate (6 mg/d) and an additional
300 IU of hCG, which was administered if the serum E2
dropped to below 800 pg/mL during close monitoring from the
2nd day to the 6th day after retrieval. For patients whose serum
E2 had never dropped below 800 pg/mL before Day 6 post
retrieval, this rescue dose was not given (Fig. 2A).
Embryos were transferred on the 3rd day or the 5th day after
retrieval depending on the number of good quality embryos
available. In protocol D, if serum E2 on Day 5 post retrieval
became even higher than those on Day 2e4 post retrieval,
under ethical considerations, all blastocysts were vitrified.
Three patients in protocol A, two patients in protocol B, zero
patients in protocol C, and one patient in protocol D under-
went “freeze-all” strategy during the study period and were
excluded from analyses. A total of 155 cycles were finally
recruited, among which 74 cycles were triggered with hCG
under downregulation protocol (Group A), 25 cycles were
triggered with hCG under the GnRH antagonist protocol
(Group B), 23 cycles were triggered with GnRHa alone
(Group C), and 33 cycles received GnRHa trigger combined
with individualized low-dose hCG support (Group D). Patients
in all groups received luteal phase support from the day after
oocyte retrieval to either 10 weeks of gestation or confirmed
failure of pregnancy.2.3. Outcome measuresFig. 2. Comparisons among different protocols of low-dose hCG supplemen-
tation in GnRHa-triggered IVF/ICSI cycles. A, Individualized low-dose hCG
support in our study. B, Dual trigger developed by Shapiro et al.13 C, Corpus
luteum rescue at oocyte retrieval raised by Humaidan.19 A fixed dose of
1500 IU hCG is administered shortly after the oocyte retrieval to rescue the
function of corpus lutea. a The dosage of hCG (500e1000 IU) in dual trigger
depends on peak E2 and the number of follicles  11 mm on trigger day:
500 IU for cycles with peak E2 >5000 pg/mL or follicle number  25; 750 IU
for cycles with peak E2 3500-5000 pg/mL and follicle number < 25; and
1000 IU for cycles with peak E2 <3500 pg/mL and follicle number < 25.
b The
additional shot of hCG 300 IU for rescue in luteal phase support: administered
if serum E2 drops to below 800 pg/mL during close monitoring from Day 2 to
Day 6 after retrieval. Otherwise, this rescue dose is not given. c 1000e2500 IU
of concomitant hCG: varied according to weight and OHSS risk factors. Pa-
tients with > 25 follicles receive an average of 23.1 IU/kg, whereas those with
 25 receive an average of 29.9 IU/kg. D2 ¼ Day 2 after oocyte retrieval;
D6 ¼ Day 6 after oocyte retrieval; E2V ¼ estradiol valerate; ET ¼ embryo
transfer; h ¼ hours; IM P ¼ intramuscular progesterone; IVF/ICSI ¼ in vitro
fertilization and/or intracytoplasmic sperm injection; OR ¼ oocyte retrieval;
rFSH ¼ recombinant follicle-stimulating hormone; Vag P ¼ vaginal-route
micronized progesterone (Crinone).Demographic variables recorded for each cycle included
the following items: age, BMI, basal FSH and LH, PCOM or
not, PCOS or not, previous OHSS or not, severe male factor
requiring ICSI or not, primary infertility or not, the number of
previous IVF attempts, and parity. Parameters in terms of
ovarian stimulation, oocytes, embryos, and cycle outcomes
were noted as follows: total gonadotropin dose, peak E2 levels,
the number of follicles on trigger day, oocyte number and
maturity, fertilization rate, cleavage rate, the number of good
available embryos, implantation rate, chemical pregnancy rate,
clinical pregnancy rate, ongoing pregnancy rate, the rate of
early pregnancy loss, the serum level of E2 and P on the 14
th
day after retrieval, and the rate of moderate/severe OHSS.
A good available embryo was defined as a six to eight cell
embryo on the 3rd day after retrieval with a grade of I or II,
according to criteria described elsewhere.15 The implantation
rate was calculated as the number of beating fetal hearts
divided by the number of embryos transferred per patient.
Positive pregnancy test was defined by the rising serum beta
subunit of human chorionic gonadotropin titers above 10 IU/L
on the 14th day after retrieval. Clinical pregnancy was counted
if any intrauterine fetal heart beat was detected by transvaginal
ultrasound 3 weeks after a positive chemical pregnancy test.
Ongoing pregnancies had surviving fetuses at 12 weeks'
gestation. Early pregnancy losses meant chemical pregnancies
that failed in developing to ongoing pregnancies. The diag-
nosis of moderate-to-severe OHSS was made according to the
criteria by Golan et al.162.4. Statistical analysesChi-square tests were used for comparisons of nominal
variables in all four groups; Fisher's exact test was used for
adjusting the expected count less than five when dealing with
2  2 tables. Continuous parameters were analyzed with
ANOVA test followed by Tukey's HSD post-hoc examinations.
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IL, USA) was used for analysis, and a p value < 0.05 was
considered to be statistically significant.
3. Results
With regards to demographic data, age, BMI, basal FSH
and LH levels, the proportion of ICSI, primary infertility and
parity were comparable among the groups (Table 1). The
proportion of patients with previous IVF attempts was
significantly higher in Group D than that in Group A.
The overall dose of gonadotropin used in Group D was
lower than that in Groups A and B (Table 2). Serum level of E2
on the day of trigger was significantly lower in Group B than
that in Groups A and D. Patients in Group D had more follicles
on the day of trigger and more oocytes retrieved than those in
Groups A and B. There was no significant difference among
the groups associated with the percentage of mature or
metaphase of second meiosis oocytes. Additionally, the
fertilization rate in Group D was higher than that in Group C.
There was no significant difference in cleavage rate among
groups. The number of good available embryos in Group D
was higher than that in Groups A and B.
None of the patients in Groups C and D developed moder-
ate/severe OHSS. By contrast, 33.8% (25/74) of the patients in
Group A and 24.0% (6/25) in Group B suffered from OHSS
(Table 3). There was a tendency toward a better outcome in
Group D than in Group C in terms of higher implantation rate
(22.5 ± 5.2% vs. 5.8 ± 2.8%), clinical pregnancy rate (48.5%
vs. 17.4%) and ongoing pregnancy rate (46.9% vs. 17.4%) as
well as lower miscarriage rate (16.7% vs. 50.0%); but probably
due to the limited case number, it did not reach statistical
significance (Table 3). With regards to the serum levels of E2
and P on the 14th day after retrieval, there was no statisticallyTable 1
Demographic data.
Characteristics of patients Group A (hCG trigger in
downregulation protocol)
Group B (hCG trigger
antagonist protocol)
Patients, n 74 25
Age (y) 32.3 ± 3.1 33.8 ± 3.3
BMI (kg/m2) 21.3 ± 2.9 22.9 ± 4.3
Basal FSH (IU/L) 5.8 ± 2.2 6.3 ± 2.8
Basal LH (IU/L) 7.2 ± 4.2 7.5 ± 7.2
PCOM 37 (50)a 11 (47.8)a
PCOS 16 (21.6)a 9 (36.0)ab
Previous OHSS 7 (9.5)a 4 (16.7)ab
Severe male factor
requiring ICSI
39 (52.7) 8 (32.0)
Primary infertility 44 (61.1) 13 (54.2)
Previous IVF attempts
0 52 (73.2) 16 (64.0)
1 19 (26.8)a 9 (36.0)ab
Parity
0 65 (87.8) 22 (88.0)
1 9 (12.2) 3 (12.0)
Data are presented as n (%) or mean ± standard deviation.
* Values in groups without the same letter are statistically different.significant difference among the groups. However, a statisti-
cally significant difference emerged when we compared serum
E2 levels exclusively in cycles with positive pregnancies tests.
On the 14th day after retrieval, serum E2 level in patients with
positive pregnancy tests was significantly higher in Group B as
compared with that in Groups C and D. Both E2 and P levels of
patients with positive pregnancy tests on the 14th day after
retrieval seemed to be higher, although not statistically signif-
icant, in Group D than in Group C (Table 3).
4. Discussion
Early luteolysis associated with GnRHa triggering is the
key to the prevention of OHSS, but at the same time it leads to
an increased rate of early pregnancy loss.17,18 To provide
adequate luteal phase support in GnRHa triggered cycles,
scientists have reported better pregnancy outcomes by sup-
plementation of exogenous intramuscular progesterone and
transdermal estradiol12 or administration of low-dose hCG as a
dual trigger13 (Fig. 2B) or as a luteal rescue19 (Fig. 2C). In our
retrospective study, we found that low-dose hCG given in
GnRHa triggered cycles was associated with improved
reproductive outcome as compared with intramuscular pro-
gesterone without hCG. However, the use of hCG in GnRHa
triggered cycles is not without risk, especially in patients at a
high risk for OHSS. Shapiro et al20 reported that even with an
hCG dose of 650 IU in combination with GnRHa trigger,
OHSS still developed in one patient among 182 high re-
sponders. The rescue dose of 1500 IU hCG given at retrieval
was associated with one case of moderate OHSS in 12 high-
risk patients in one report,19 and one case of severe OHSS
in 71 women with high OHSS risk in another study.21
The rationale for the individualized low-dose hCG we
administered in GnRHa-triggered cycles was the idea ofin Group C (GnRHa trigger in
antagonist protocol)
Group D (GnRHa
trigger þ individualized
hCG in antagonist protocol)
p
23 33
32.6 ± 3.1 33.5 ± 4.1 0.153
22.0 ± 3.0 22.1 ± 4.3 0.259
6.6 ± 1.8 6.5 ± 1.7 0.330
8.2 ± 3.3 9.2 ± 7.2 0.363
18 (78.3)ab 28 (84.8)b 0.002*
5 (21.7)a 20 (60.6)b 0.001*
7 (30.4)ab 15 (45.5)b <0.001*
11 (55.0) 15 (45.5) 0.296
17 (73.9) 20 (60.6) 0.561
16 (69.6) 14 (43.8) 0.034*
7 (30.4)ab 18 (56.3)b
20 (87.0) 26 (78.8) 0.635
3 (13.0) 7 (21.2)
Table 2
Stimulation characteristics and data of oocytes and embryos.
Variable Group A (hCG
trigger in
downregulation
protocol)
Group B
(hCG trigger in
antagonist
protocol)
Group C
(GnRHa trigger
in antagonist
protocol)
Group D (GnRHa
trigger þ individualized
hCG in antagonist
protocol)
p
Patients, n 74 25 23 33
Total dose of gonadotropin (IU) 2790 ± 678b 3005 ± 567b 2469 ± 917ab 2357 ± 873a 0.008*
E2 on day of trigger (pg/mL) 5182 ± 2113
b 3893 ± 1673a 4663 ± 1545ab 5390 ± 2212b 0.024*
Follicles on trigger day 18.3 ± 5.5a 15.6 ± 7.1a 20.1 ± 5.7ab 22.7 ± 8.0b 0.001*
Oocytes 14.7 ± 6.4a 14.0 ± 8.6a 18.5 ± 7.1ab 23.4 ± 10.5b <0.001*
Rate of mature oocytes,% 77.5 ± 20.1 79.9 ± 21.7 80.8 ± 18.5 74.6 ± 18.1 0.647
Rate of MII oocytes in ICSI cycles, % 70.4 ± 20.5 70.7 ± 19.4 70.5 ± 24.3 74.2 ± 19.7 0.941
Fertilization rate,% 75.4 ± 16.0ab 73.4 ± 19.1ab 68.5 ± 20.7a 82.2 ± 10.0b 0.022*
Cleavage rate, % 85.4 ± 15.3 79.7 ± 16.5 84.2 ± 16.3 82.7 ± 16.4 0.460
Good available embryos 3.2 ± 1.8a 2.5 ± 1.7a 3.4 ± 2.7ab 4.6 ± 2.6b 0.004*
Data are presented as mean ± standard deviation.
MII ¼ metaphase of second meiosis.
* Values in groups without the same letter are statistically different.
Table 3
Cycle outcomes of all patients and serum E2 and P levels on Day 14 after oocyte retrieval in patients with positive pregnancy tests.
Variable Group A (hCG
trigger in
downregulation
protocol)
Group B
(hCG trigger in
antagonist
protocol)
Group C
(GnRHa trigger
in antagonist
protocol)
Group D (GnRHa
trigger þ individualized
hCG in antagonist
protocol)
p
Patients, n 74 25 23 33
Moderate-to-severe OHSS rate 25 (33.8) 6 (24.0) 0 (0) 0 (0) <0.001
E2 on Day 14 after oocyte retrieval (pg/mL) 2313 ± 2275 2387 ± 2340 1373 ± 708 1523 ± 1032 0.078
P on Day 14 after oocyte retrieval (ng/mL) 137.7 ± 153.3 145.9 ±163.0 65.0 ± 68.4 143.3 ± 147.9 0.215
Implantation rate (%) 17.0 ± 3.2 14.2 ± 4.8 5.8 ± 2.8 22.5 ± 5.2 0.129
Positive pregnancy test 32 (43.2) 10 (41.7) 8 (34.8) 19 (57.6) 0.351
Clinical pregnancy rate 26 (35.1) 8 (33.3) 4 (17.4) 16 (48.5) 0.122
Ongoing pregnancy rate 24 (32.9) 6 (27.3) 4 (17.4) 15 (46.9) 0.129
Early pregnancy loss 7 (22.6) 2 (25.0) 4 (50.0) 3 (16.7) 0.326
Patients with positive pregnancy tests, n 32 10 8 19
E2 on Day 14 after oocyte retrieval (pg/mL) 3343 ± 2295
ab 4178 ± 2430b 1512 ± 833a 2120 ± 980a 0.006*
P on Day 14 after oocyte retrieval (ng/mL) 233.1 ± 173.9 287.3 ±161.9 77.8 ± 96.9 202.2 ± 173.0 0.063
Data are presented as n (%) or mean ± standard deviation.
* Values in groups without the same letter are statistically different.
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pregnancy outcome with no OHSS. This was achieved by
means of low-dose hCG divided into 500e1000 IU for com-
bined trigger and then 300 IU for rescuing corpus luteum if
needed. We closely monitored serum E2 level from the 2
nd day
to the 6th day after retrieval, in order to timely administer the
rescue dose of 300 IU hCG if serum E2 dropped to below
800 pg/mL. We tailored the timing to boost a bolus of low-
dose hCG before Day 6 post retrieval. This timing referred
to the length of the luteal phase documented after GnRHa
trigger alone, which was around 4 days at the shortest, as
referenced in the literature.22 If serum E2 was above 800 pg/
mL on Day 6 post retrieval, the 300 IU rescue dose of hCG
was not given in order to avoid OHSS, and the corpus luteum
was expected to be partially rescued by implanted trophoblast-
derived hCG from Day 9 of retrieval should pregnancy occur.
We observed that 300 IU of hCG would offer 2e3 additional
days of corpus luteum support. If serum E2 on the 5
th day after
retrieval became even higher than those on Days 2e4 afterretrieval (which occurred in only 1 patient receiving dual
trigger during the study period), all blastocysts were cry-
opreserved to prevent late-onset OHSS. We believe that this
approach will make the high responders much safer.
We intentionally applied the tailored approach with low-
dose of hCG (Group D) and GnRHa trigger alone (Group C)
for the high responders identified by the characteristics of
PCOM, PCOS, or previous OHSS. When compared with
Groups C and D, more high responders (enrolled by peak
E2  2500 pg/mL) in Groups A and B had no known pre-
disposing factors and became apparent during ovarian stimu-
lation. Owing to the study design and the inherent limitation in
the nonrandomized retrospective study, some confounding
factors were distributed unevenly in each group. Groups C and
D had more patients with PCOM, PCOS, or previous OHSS
(Table 1); however, no patient in Groups C and D experienced
OHSS and an ongoing pregnancy rate of 46.9% was achieved
in Group D. It was the good reproductive outcome with zero
OHSS rate in an even higher percentage of high-risk
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GnRHa trigger with individualized low-dose hCG support.
A presumed advantage of concomitant hCG in GnRHa
trigger is to aid in oocyte maturation, as well as its benefit to
luteal support. Although there is no significant difference in
the oocyte maturity among the four groups, our data revealed a
higher fertilization rate in Group D (mean 82.2%), signifi-
cantly when compared with Group C (mean 68.5%) and
nonsignificantly when compared with Groups A (mean 75.4%)
and B (mean 73.4%), respectively. Except for the fertilization
rate of 62.8% in dual trigger reported by Shapiro et al13 and
the fertilization rate of 79.2% in dual trigger reported by
Griffin et al,23 there was limited data in reference to the
fertilization rate in cycles triggered by GnRHa combined with
hCG. As for GnRHa trigger alone versus hCG trigger, previous
investigations showed similar fertilization rates.9,14,24 The
possible explanation for better fertilization in our combined
trigger might be that low-dose of hCG could assist final
maturation of oocytes in aspects not detectable by the
morphology, which needs further validation via well-designed
prospective trials. We assumed both the higher fertilization
rate and superior luteal support contributed to a better preg-
nancy outcome as compared with the group receiving GnRH
agonist trigger alone.
Although mean E2 level on trigger day in group D reached
5390 pg/mL, an ongoing pregnancy rate of 46.9%was achieved.
Extremely high level of peak E2 in this group did not seem to
impair the reproductive outcome, which conflicted with the
previous concept that high E2 level would impede implanta-
tion.25,26 A possible explanation could be that the high re-
sponders per se produced plenty of oocytes to be fertilized, and
further led to sufficient embryos to be selected. Thus, the
resulting blastocysts transferred into the uterus might be
“strong” enough to overcome the inferior environment.Whether
this hypothesis is correct needs further investigation.
In view of the implantation rate (22.5% vs. 5.8%), clinical
pregnancy rate (48.5% vs. 17.4%), and ongoing pregnancy rate
(46.9% vs. 17.4%) for Group D versus Group C, there was a
tendency toward a better outcome in the group of agonist plus
individualized low-dose hCG support (Group D) versus agonist
trigger alone (Group C). The rate of early pregnancy loss
(16.7% and 50.0% for Groups D and C, respectively) seems to
be higher in the group of agonist trigger alone. Probably due to
the limited case number, it did not reach statistical significance.
In Group D, there was a trend toward higher serum E2
(1523 pg/mL vs. 1373 pg/mL for Group D vs. Group C) and P
(143.3 ng/mL vs. 65.0 ng/mL for Group D vs. Group C) levels
on the 14th day after oocyte retrieval as compared with Group
C, although statistical significance was not reached. If we
focused on the population with positive pregnancy tests (Table
3), serum E2 level on the 14
th day after oocyte retrieval in
Group D (2120 pg/mL) was significantly lower than that in
Group B (hCG trigger in antagonist cycles, 4178 pg/mL), and
slightly higher (nonsignificantly) than that in Group C
(1512 pg/mL). Regarding the P level on the14th day after
oocyte retrieval in the population with positive pregnancy tests,
there was a similar tendency, i.e., the P level in Group D waslower than that in Group B and higher than that in Group C
(Group B, 287.3 ng/mL; Group C, 77.8 ng/mL; and Group D,
202.2 ng/mL), although statistical significance was not reached.
This status was what we managed to achieve: to rescue only a
small portion of the corpus lutea awaiting subsequent endog-
enous hCG to sustain it, merely satisfying pregnancy mainte-
nance, but not to the level toward OHSS.
To date, conclusions from the existing meta-analyses for
GnRHa trigger were the results of either analyzing data from
studies recruiting normo-ovulatorywomen9 or pooling data from
studies enrolling normal and high responders.8,18 The authors in
Kolibianakis et al27 have proposed a view of examining the
various surveys onGnRHa trigger in two categories: patients at a
normal risk for OHSS and those with a high risk of OHSS. With
this view, we reviewed and summarized investigations involving
GnRHa triggering combined with supplementation of low-dose
hCG, as described below. In patients at a normal risk for
OHSS, low-dose hCG resulted in comparable pregnancy out-
comes in GnRHa-triggered groups as compared with hCG-
triggered groups. However, no difference could be concluded
regarding OHSS incidence after GnRHa triggering versus con-
ventional hCG triggering, because either no cases of OHSSwere
reported in either group28 or the study was not powered to detect
differences in OHSS rate.14,29 As for high responders receiving
GnRHa triggering, low-dose hCG administration either on the
day of oocyte retrieval19,21 or in the form of dual trigger,20 can
provide good pregnancy rates with a low but not zero rate of
OHSS. A retrospective study conducted by Griffin et al23 used a
dual triggerwithGnRHa and 1000 IU of hCG in selected patients
at risk of OHSS with peak E2 < 4000 pg/mL, reporting a
significantly higher pregnancy rate as compared with GnRHa
trigger alone, as well as only one case of mild OHSS in 34 pa-
tients receiving dual trigger. In our present studywith the tailored
approach, none of the 33 patients in Group D with mean peak E2
exceeding 5000 pg/mL experienced OHSS. Therefore, hCG is
like a double-edged sword from which patients cannot benefit
until we find not only the predicting parameters to select themost
appropriate population but also the optimal way to tailor the dose
individually. Moreover, individualized low-dose hCG supple-
mentation may provide a more patient-friendly way of luteal
support instead of painful progesterone injection. A preliminary
report from Kol et al30 suggested that two boluses of 1500 IU
hCG, without any additional luteal support containing proges-
terone, could revert the luteolysis after a GnRHa trigger in the
normal responders. Thus, we can anticipate that once the optimal
dose-tailoring approach is confirmed, the patientswould be freed
from painful intramuscular P injection and achieve good preg-
nancy outcomes without experiencing OHSS.
In conclusion, GnRHa trigger in combination with tailored
low-dose hCG support seems to be a safe approach with a
satisfactory pregnancy outcome for high responders, in
contrast to high OHSS rate in hCG-triggered cycles and low
pregnancy rate in GnRHa-triggered cycles without hCG.
Further larger randomized controlled trials should be pursued
to refine this protocol so that a patient-friendly regimen can be
finalized to obtain excellent reproductive outcome and to
almost completely avoid OHSS.
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